荷爾蒙避孕藥市場規模、佔有率、成長分析（按產品、按激素、按年齡、按最終用戶、按地區）- 產業預測，2025 年至 2032 年

2023 年全球荷爾蒙避孕藥市場規模價值 193 億美元，預計將從 2024 年的 201.1 億美元成長到 2032 年的 279.5 億美元，預計在預測期內（2025-2032 年）到 2032 年將達到 202.9 億美元)。

全球荷爾蒙避孕藥市場預計將大幅成長，預計 2022 年至 2030 年的複合年成長率約為 4.5%。這種成長主要是由於人們對避孕方法的認知和接受度不斷提高、性行為感染感染（STI）盛行率不斷上升以及對有效計劃生育解決方案的需求不斷增加。口服避孕藥因其有效性和便利性而佔據市場主導地位，尤其是含有雌激素和黃體素的複方藥。然而，由於僅含孕激素的避孕藥非常適合無法使用雌激素的女性且副作用較少，因此越來越受歡迎，因此預計未來其成長將會加速。由於性傳染​​感染預防的局限性，同時使用保險套仍然很重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

荷爾蒙避孕藥市場規模（依產品分類）

• 市場概況
• 口服避孕藥
• 注射避孕藥
• 事後緊急避孕藥
• 避孕環
• 經皮吸收貼片

荷爾蒙避孕市場規模（依荷爾蒙分列）

• 市場概況
• 僅含黃體素的避孕藥
• 合併荷爾蒙避孕藥

荷爾蒙避孕藥市場規模（依年齡分類）

• 市場概況
• 15-24歲
• 25-34歲
• 35-44歲
• 年齡 44 歲或以上

荷爾蒙避孕藥市場規模（以最終用戶分類）

• 市場概況
• 醫院
• 適合家庭使用
• 診所

荷爾蒙避孕藥市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（USA）
• Viatris Inc.（USA）
• Organon & Co.（USA）
• Mithra Pharmaceuticals（Belgium）
• Agile Therapeutics, Inc.（USA）
• Mayne Pharma Group Limited（Australia）
• Afaxys, Inc.（USA）
• Pregna International Ltd.（India）
• Lupin Pharmaceuticals Inc.（India）
• Cipla Limited（India）
• Sun Pharmaceutical Industries Limited（India）
• Piramal Enterprises Limited（India）

結論和建議

Global Hormonal Contraceptive Market size was valued at USD 19.3 billion in 2023 and is poised to grow from USD 20.11 billion in 2024 to USD 27.95 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global hormonal contraceptive market is poised for significant growth, projected to expand at a compound annual growth rate (CAGR) of around 4.5% between 2022 and 2030. This growth is largely fueled by increasing awareness and acceptance of contraceptive methods, a rising incidence of sexually transmitted infections (STIs), and heightened demand for effective family planning solutions. Oral contraceptives dominate the market, particularly combination pills that contain both estrogen and progestin, thanks to their effectiveness and convenience. However, progestin-only pills are gaining traction, anticipated to grow faster due to their minimal side effects, making them ideal for women who cannot use estrogen. Given their limitations in preventing STIs, the concurrent use of condoms remains crucial for protection.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segmental Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

A significant driver of the global hormonal contraceptive market is the rising awareness and acceptance of contraception for family planning purposes. As population levels continue to surge, especially in developing nations, there is an escalating demand for reliable birth control solutions that enable couples to control family size and spacing effectively. This growing recognition of the importance of contraception has resulted in a notable uptick in the utilization of hormonal contraceptives, which are celebrated for their high efficacy in preventing unintended pregnancies while providing a user-friendly and reversible option for individuals seeking to manage their reproductive health.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable constraints due to various social and cultural factors that hinder women's access to contraceptive methods. In numerous cultures and communities, contraception is often stigmatized, and certain religious doctrines explicitly forbid its use. Furthermore, a significant lack of awareness and education surrounding contraceptive options exists in many areas globally, contributing to diminished demand for such products. These intertwined social and cultural influences can significantly impede market growth, particularly in regions where such factors heavily influence the choices regarding contraceptive usage. Addressing these challenges is crucial for expanding access to hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a pronounced shift towards Long-Acting Reversible Contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal implants, reflecting a significant trend among consumers. These methods offer high efficacy in preventing unintended pregnancies while providing extended duration of use, appealing particularly to younger women and those desiring reliable, low-maintenance contraception. This growing preference is driven by increasing awareness of reproductive health options, enhanced convenience, and the desire for a hassle-free experience. As a result, LARCs are rapidly gaining traction, reshaping the landscape of hormonal contraceptive solutions worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2025-2032)

• Market Overview
• Oral Contraceptive Pills
• Injectable Birth Control
• Emergency Contraceptive Pills
• Vaginal Rings
• Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2025-2032)

• Market Overview
• Progestin Only Contraceptive
• Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2025-2032)

• Market Overview
• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Household
• Clinics

Global Hormonal Contraceptive Market Size & CAGR (2025-2032)

• North America (Product, Hormones, End User, Age)
  • US
  • Canada
• Europe (Product, Hormones, End User, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Hormones, End User, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Hormones, End User, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Hormones, End User, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations